Bio-Thera Solutions, Ltd. Class A 688177

Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8013, an antibody drug conjugate (ADC) that targets CD25. The clinical trial is a multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors to evaluate the safety and tolerability of BAT8013 and to determine the recommended Phase 2 dose.

Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas"), focused on the development of oncology, immunology and central nervous system (CNS) therapies, today announced Accord BioPharma received marketing authorization in the United States of America for IMMGOLIS (formerly known as BAT2506), a SIMPONI® (golimumab) bios

Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced a further expansion of its partnership with Intas Pharmaceuticals for BAT2506, a proposed golimumab biosimilar, through an exclusive commercialization and license agreement for India.

Recently published Neuromyelitis Optica Spectrum Disorder Market Insights report includes a comprehensive understanding of current treatment practices, neuromyelitis optica spectrum disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].